Remedium Lifecare Ltd
₹ 2.66
-5.00%
28 Feb
- close price
About
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
Key Points
- Market Cap ₹ 107 Cr.
- Current Price ₹ 2.66
- High / Low ₹ 33.2 / 2.66
- Stock P/E
- Book Value ₹ 1.14
- Dividend Yield 0.00 %
- ROCE 99.5 %
- ROE 123 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 101%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 1.11%
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 2 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 510 | 4,040 | 1,549 | |
1 | 1 | 2 | 4 | 1 | 0 | 0 | 2 | 89 | 503 | 502 | 4,006 | 1,585 | |
Operating Profit | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 2 | 8 | 34 | -36 |
OPM % | 7% | 3% | -8% | -8% | -7% | 0% | -44% | 14% | 1% | 0% | 2% | 1% | -2% |
0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 13 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 50 | -30 |
Tax % | 0% | 50% | 21% | 0% | 0% | 0% | 100% | 24% | 26% | 29% | 27% | 35% | |
0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 33 | -50 | |
EPS in Rs | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.13 | 0.81 | -1.23 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 659% |
3 Years: | 255% |
TTM: | -43% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 405% |
3 Years: | 309% |
TTM: | -194% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 71% |
3 Years: | 30% |
1 Year: | -92% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 88% |
3 Years: | 101% |
Last Year: | 123% |
Balance Sheet
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 40 |
Reserves | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -0 | 0 | 1 | 7 | 33 | 6 |
1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 58 | 181 | |
2 | 1 | 3 | 2 | 0 | 0 | 0 | 1 | 24 | 219 | 1,144 | 1,847 | 1,924 | |
Total Liabilities | 6 | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 2,152 |
2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
4 | 4 | 4 | 5 | 3 | 3 | 4 | 4 | 38 | 224 | 1,154 | 1,948 | 2,152 | |
Total Assets | 6 | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 2,152 |
Cash Flows
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | -1 | 0 | -0 | -0 | -0 | -10 | 11 | 20 | -74 | |||
0 | 1 | 0 | 0 | 1 | -0 | -0 | -0 | -0 | 0 | |||
-0 | -0 | 0 | 0 | 0 | 0 | 10 | -11 | -0 | 54 | |||
Net Cash Flow | -0 | 0 | 0 | -0 | 1 | -0 | -0 | 1 | 20 | -20 |
Ratios
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 203 | 120 | 341 | 265 | 596 | 2,117 | 319 | 189 | 96 | 46 | 123 | 83 |
Inventory Days | 1,506 | 1,129 | 243 | 78 | 0 | 0 | 5 | 12 | ||||
Days Payable | 162 | 102 | 438 | 129 | 62 | 65 | ||||||
Cash Conversion Cycle | 1,547 | 1,147 | 146 | 214 | 596 | 2,117 | 319 | 189 | 96 | 46 | 67 | 30 |
Working Capital Days | 607 | 566 | 107 | 200 | 524 | 2,159 | 4,745 | 323 | 54 | 2 | -8 | 9 |
ROCE % | 1% | 1% | 0% | 1% | 1% | 11% | 7% | 18% | 103% | 100% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Feb - Submission of Newspaper Clippings regarding Unaudited Financial Results for the quarter and Nine Months ended 31.12.2024
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
15 Feb - Received multi-year supply contract worth Rs.182.7 Crores.
-
Integrated Filing (Financial)
14 Feb - Submission of unaudited financial results for Q3 2024.
-
Results For The Quarter And Nine Months Ended December 31, 2024.
14 Feb - Review report on unaudited financial results for Q3 2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, February 14, 2025.
14 Feb - Approved unaudited financial results for Q3 FY2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets